CompletedEarly Phase 1

Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma

Egypt50 participantsStarted 2024-02-09

Plain-language summary

To asess the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * children under 12 years with previous AGV implantation for primary congenital glaucoma Exclusion Criteria: * age \>12 years, eyes with no light perception, and those with prior cyclodestructive procedures.

What they're measuring

surgical success

Timeframe: for 12 months

Trial details

NCT IDNCT06983704

SponsorBenha University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-08

View on ClinicalTrials.gov More Pediatric Glaucoma trials